Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.58 |
| ▸ | MET | P08581 | 2/20 | 0.52 |
| ▸ | PLK1 | P53350 | 2/20 | 0.46 |
| ▸ | INSR | P06213 | 5/20 | 0.45 |
| ▸ | ALK | Q9UM73 | 5/20 | 0.45 |
| ▸ | IGF1R | P08069 | 4/20 | 0.45 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.44 |
| ▸ | BTK | Q06187 | 2/20 | 0.44 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.43 |
| ▸ | PLK4 | O00444 | 1/20 | 0.43 |
| ▸ | STK25 | O00506 | 1/20 | 0.43 |
| ▸ | RIOK3 | O14730 | 1/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | CASK | O14936 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | GAK | O14976 | 1/20 | 0.43 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.43 |
| ▸ | MUSK | O15146 | 1/20 | 0.43 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30860746 | 0.93 | EGFR (0.54) | EGFRMETPLK1PTK2BTK | |
| SCHEMBL30860424 | 0.92 | EGFR (0.56) | EGFRMETPLK1INSRALK | |
| SCHEMBL30860759 | 0.92 | EGFR (0.56) | EGFRMETPTK2BTKCHEK1 | |
| SCHEMBL30860400 | 0.90 | EGFR (0.54) | EGFRMETPLK1INSRALK | |
| SCHEMBL25001806 | 0.90 | EGFR (0.49) | EGFRMETALKBTKMAP4K1 | |
| SCHEMBL25001385 | 0.90 | EGFR (0.60) | EGFRINSRALKBTKULK1 | |
| SCHEMBL25002690 | 0.89 | EGFR (0.57) | EGFRPLK1INSRALKIGF1R | |
| SCHEMBL30860273 | 0.87 | EGFR (0.53) | EGFRMETPTK2BTKCHEK1 | |
| SCHEMBL30860752 | 0.86 | EGFR (0.55) | EGFRMETPLK1PTK2BTK | |
| SCHEMBL30860750 | 0.86 | EGFR (0.55) | EGFRMETPLK1INSRALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219986-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | QILU PHARMACEUTICAL CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
| US-20230219986-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | QILU PHARMACEUTICAL CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
| EP-4129996-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | QILU PHARMACEUTICAL CO., LTD. (CN) | 2023-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219986-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | EGFR, ERBB2, ERBB4 | EGFR 1/4885MET 10/4885PLK1 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.